血漿療法市場：タイプ別、用途別-2025-2030年の世界予測

血漿療法市場は、2023年に3億5,973万米ドルと評価され、2024年には3億8,919万米ドルに達すると予測され、CAGR 11.73%で成長し、2030年には7億8,195万米ドルに達すると予測されています。

血漿療法、特に回復期の血漿療法の文脈では、感染症から回復した個人の血漿の輸血が含まれます。血漿療法の適用範囲は、血漿中に存在する中和抗体を利用したウイルス感染症の治療にも及ぶ。特に、特定の治療法やワクチンが利用できないような疾病が発生した場合には、極めて重要な治療手段となります。用途は回復期、免疫グロブリン療法、治療用血漿交換に及び、最終用途は主に病院、学術研究機関、治療センターです。この市場を牽引しているのは、自己免疫疾患の罹患率の上昇と、COVID-19のような生命を脅かすウイルス感染症の治療法改善の必要性の高まりです。さらに、高齢化により血漿提供者が継続的に流入し、市場拡大を促進しています。研究と技術の進歩は新たな市場機会を約束し、有効性と安全性を高めるための血漿採取と保存技術の革新を促します。しかし、市場は規制の不確実性、輸血感染症のリスク、血漿需給バランスにおける物流のハードルといった大きな課題に直面しています。治療の標準化も大きな障壁となっており、治療結果にばらつきが生じる可能性があります。この市場開拓には、効率的な血漿分離・処理のための自動化装置の開発が含まれます。また、血漿の有効性を高めるための遺伝子工学を対象とした調査も可能です。学術界、臨床界、産業界の利害関係者が協力することで、新しいプロトコールの開発や新規血漿使用例の特定が加速される可能性があります。このような努力は市場競争を促進し、治療の選択肢を広げるであろう。このように市場力学はダイナミックであり、潜在的な成長は物流や規制の複雑さによって抑制されています。イノベーションと戦略的パートナーシップを重視することで、こうした障壁を克服し、新たな成長機会を開拓する道筋を示すことができます。

市場力学：急速に進化する血漿療法市場の主要市場インサイトを公開

血漿療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の感染症および慢性疾患の流行
  • 疾病の早期診断と治療への傾斜
  • 血漿療法の有効性を検証する臨床試験の増加
• 市場抑制要因
  • 血漿療法治療費の高騰
• 市場機会
  • 血小板を豊富に含む血漿療法の進歩
  • 皮膚科学における血漿療法の新たな使用法
• 市場の課題
  • 血漿療法に伴う副作用

ポーターの5つの力：血漿療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、血漿療法市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血漿療法市場における外部からの影響の把握

外部マクロ環境要因は、血漿療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血漿療法市場における競合情勢の把握

血漿療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血漿療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血漿療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血漿療法市場における成功への道筋を描く

血漿療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中の感染症と慢性疾患の蔓延
    • 病気の早期診断と治療への傾向
    • 血漿療法の有効性をテストするための臨床試験の増加
  • 抑制要因
    • 血漿療法治療のコストが高い
  • 機会
    • 血小板濃縮の進歩血漿療法
    • 皮膚科における血漿療法の新たな利用
  • 課題
    • 血漿療法に関連する悪影響
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血漿療法市場：タイプ別

• 白血球を多く含むPRP
• 白血球含有フィブリン（L-PRF）
• 純粋血小板フィブリン（PRF）
• 純粋PRP

第7章 血漿療法市場：用途別

• 歯科
• 皮膚科
• 神経損傷
• 整形外科

第8章 南北アメリカの血漿療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の血漿療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの血漿療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• ADMA Biologics, Inc.
• Arthrex, Inc.
• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products, Inc.
• CSL Limited
• Emergent BioSolutions Inc.
• Exactech Inc.
• GC Pharma
• Global Stem Cells Group, Inc.
• Green Cross Corporation
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Interstate Blood Bank, Inc.
• Japan Blood Products Organization
• Johnson & Johnson Services, Inc.
• Kedrion S.p.A.
• LFB S.A.
• Octapharma AG
• Regen Lab SA
• Shanghai RAAS Blood Products Co., Ltd.
• Stryker Corporation
• Takeda Pharmaceutical Company Limited
• Terumo Corporation
• Zimmer Biomet Holdings, Inc

LIST OF FIGURES

• FIGURE 1. PLASMA THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. PLASMA THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PLASMA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PLASMA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PLASMA THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PLASMA THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PLASMA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PLASMA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PLASMA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PLASMA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PLASMA THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PLASMA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PLASMA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PLASMA THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PLASMA THERAPY MARKET SIZE, BY LEUCOCYTE-RICH PRP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PLASMA THERAPY MARKET SIZE, BY LEUKOCYTE-RICH FIBRIN (L-PRF), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PLASMA THERAPY MARKET SIZE, BY PURE PLATELET-RICH FIBRIN (PRF), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PLASMA THERAPY MARKET SIZE, BY PURE PRP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PLASMA THERAPY MARKET SIZE, BY NERVE INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. CANADA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. CANADA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES PLASMA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CHINA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CHINA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. INDIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ITALY PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ITALY PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. POLAND PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. POLAND PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. QATAR PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. QATAR PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM PLASMA THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. PLASMA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 104. PLASMA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Plasma Therapy Market was valued at USD 359.73 million in 2023, expected to reach USD 389.19 million in 2024, and is projected to grow at a CAGR of 11.73%, to USD 781.95 million by 2030.

Plasma therapy, especially in the context of convalescent plasma therapy, involves the transfusion of plasma from individuals who have recovered from infections. The scope of plasma therapy extends to its application in treating viral infections by utilizing neutralizing antibodies present in the plasma. It is a crucial therapeutic tool, particularly for disease outbreaks where specific treatments or vaccines are unavailable. The application spans convalescent plasma therapy, immunoglobulin therapy, and therapeutic plasma exchange, with end-use mainly in hospitals, academic research institutes, and therapeutic centers. The market is driven by rising incidences of autoimmune diseases and the increased necessity for improved treatments for life-threatening viral infections like COVID-19. Additionally, the aging population presents a continuous influx of plasma donors, thereby facilitating market expansion. Advancements in research and technology promise new market opportunities, inviting innovation in plasma collection and storage techniques to enhance efficacy and safety. However, the market faces substantial challenges such as regulatory uncertainties, risks of transfusion-transmitted infections, and logistical hurdles in plasma supply and demand balance. A significant barrier remains the standardization of therapies, which can lead to varied treatment outcomes. Innovating within this market could involve developing automated devices for efficient plasma separation and processing. Research could also target genetic engineering to enhance plasma efficacy. Collaborations across academic, clinical, and industry stakeholders could accelerate the development of new protocols and the identification of novel plasma-use-cases. These efforts will drive market competitiveness and broaden therapeutic options. The plasma therapy market is thus dynamic, with potential growth tempered by logistical and regulatory complexities. Emphasizing innovation and strategic partnerships can provide a pathway to overcoming these barriers and exploiting new growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Therapy Market

The Plasma Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of infectious and chronic diseases worldwide
  • Inclination towards early diagnosis and treatment of diseases
  • Increase in number of clinical trials to test efficacy of plasma therapy
• Market Restraints
  • High cost of plasma therapy treatment
• Market Opportunities
  • Advancements in platelet-rich plasma therapy
  • Emerging use of plasma therapy in dermatology
• Market Challenges
  • Adverse effects associated with the plasma therapy

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Therapy Market

A detailed market share analysis in the Plasma Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Plasma Therapy Market

A strategic analysis of the Plasma Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Plasma Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., ADMA Biologics, Inc., Arthrex, Inc., Bio Products Laboratory Ltd., Biotest AG, China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Exactech Inc., GC Pharma, Global Stem Cells Group, Inc., Green Cross Corporation, Grifols, S.A., Hualan Biological Engineering Inc., Interstate Blood Bank, Inc., Japan Blood Products Organization, Johnson & Johnson Services, Inc., Kedrion S.p.A., LFB S.A., Octapharma AG, Regen Lab SA, Shanghai RAAS Blood Products Co., Ltd., Stryker Corporation, Takeda Pharmaceutical Company Limited, Terumo Corporation, and Zimmer Biomet Holdings, Inc.

Market Segmentation & Coverage

This research report categorizes the Plasma Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Leucocyte-rich PRP, Leukocyte-rich Fibrin (L-PRF), Pure Platelet-rich Fibrin (PRF), and Pure PRP.
• Based on Application, market is studied across Dental, Dermatology, Nerve Injury, and Orthopedics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of infectious and chronic diseases worldwide
    • 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
    • 5.1.1.3. Increase in number of clinical trials to test efficacy of plasma therapy
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of plasma therapy treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in platelet-rich plasma therapy
    • 5.1.3.2. Emerging use of plasma therapy in dermatology
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the plasma therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Plasma Therapy Market, by Type

• 6.1. Introduction
• 6.2. Leucocyte-rich PRP
• 6.3. Leukocyte-rich Fibrin (L-PRF)
• 6.4. Pure Platelet-rich Fibrin (PRF)
• 6.5. Pure PRP

7. Plasma Therapy Market, by Application

• 7.1. Introduction
• 7.2. Dental
• 7.3. Dermatology
• 7.4. Nerve Injury
• 7.5. Orthopedics

8. Americas Plasma Therapy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Plasma Therapy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Plasma Therapy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. ADMA Biologics, Inc.
• 3. Arthrex, Inc.
• 4. Bio Products Laboratory Ltd.
• 5. Biotest AG
• 6. China Biologic Products, Inc.
• 7. CSL Limited
• 8. Emergent BioSolutions Inc.
• 9. Exactech Inc.
• 10. GC Pharma
• 11. Global Stem Cells Group, Inc.
• 12. Green Cross Corporation
• 13. Grifols, S.A.
• 14. Hualan Biological Engineering Inc.
• 15. Interstate Blood Bank, Inc.
• 16. Japan Blood Products Organization
• 17. Johnson & Johnson Services, Inc.
• 18. Kedrion S.p.A.
• 19. LFB S.A.
• 20. Octapharma AG
• 21. Regen Lab SA
• 22. Shanghai RAAS Blood Products Co., Ltd.
• 23. Stryker Corporation
• 24. Takeda Pharmaceutical Company Limited
• 25. Terumo Corporation
• 26. Zimmer Biomet Holdings, Inc